NT-I7 enhanced the efficacy of CAR-T therapy against acute myeloid leukemia and B cell lymphoma, significantly prolonging survival in murine models. NT-I7.
NeoImmuneTech, Inc. , a clinical-stage T cell-focused biopharmaceutical company, today announced that new data from two clinical trials evaluating the company’s lead asset NT-I7 will be.
Greenberg Traurig Represents NeoImmuneTech, Inc. in KOSDAQ IPO
Share Article
Global law firm Greenberg Traurig, LLP represented NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, in connection with its initial public offering (IPO) on the Korea Exchange (KOSDAQ). WILMINGTON, Del. (PRWEB) April 01, 2021 Global law firm Greenberg Traurig, LLP represented NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, in connection with its initial public offering (IPO) on the Korea Exchange (KOSDAQ).
As part of the IPO, the company sold 3,133,334 shares of common stock, equivalent to 15,666,670 Korea Depository Receipts (KDRs), priced at KRW 37,500 per share. The aggregate gross proceeds to NeoImmuneTech, before deducting underwriting discounts and commissions and other offering expenses, were KRW 117.5 billion ($103.4 million). NeoImmuneTech trades under the KOSDAQ co
Posted on 328
NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, today announced the appointment of Byung Ha Lee, Ph.D., as Chief Scientific Officer (CSO) effective March 1
st, 2021. Dr. Lee brings extensive scientific experience to the leadership team, with over 15 years of diverse drug development experience. In this new role, Dr. Lee will lead the effort to further demonstrate the scientific strength and maximize the scientific value of the Company’s products.
“Dr. Lee has been an integral part of our company’s success thus far, and we look forward to his continued scientific leadership as our company moves into the next phase of development and growth,” said Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech (NIT). “The scientific merit of our lead drug candidate, NT-I7, is much attributed to the strong leadership Dr. Lee has provided to NIT over the p